Literature DB >> 545644

Liver involvement in essential mixed cryoglobulinemia.

S Bombardieri, C Ferri, O Di Munno, G Pasero.   

Abstract

Twenty-one of 30 patients with essential mixed cryoglobulinemia (EMC) had evidence of liver involvement. The liver disease was characterized by the absence of clinical symptoms, hepatosplenomegaly, mild elevation of enzymes, abnormal BSP retention and low albumin levels. Histology, available in 12 patients, showed either chronic persistent or chronic active hepatitis or liver cirrhosis; 44% of the patients had HBsAg or HBsAb in sera and/or cryoglobulins, confirming the high frequency of exposure to hepatitis B virus (HBV) infection in EMC. However, liver lesions were similar in all patients, regardless of HBV exposure. Since other factors usually associated with chronic liver diseases were absent or apparently irrelevant, it is temptative to speculate that a 'cryoglobulinemic hepatitis' may exist as a distinct syndrome. The characteristic complement profile of the patients with EMC (low CH50 and C4, normal C3PA), not related to albumin levels, can help to differentiate this disease from chronic liver disease without cryoglobulins.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 545644     DOI: 10.1007/BF02904572

Source DB:  PubMed          Journal:  Ric Clin Lab        ISSN: 0390-5748


  10 in total

1.  Antibodies against hepatitis C virus in mixed cryoglobulinemia patients.

Authors:  C Ferri; F Greco; G Longombardo; P Palla; A Moretti; E Marzo; P V Fosella; G Pasero; S Bombardieri
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 2.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Cryoglobulins.

Authors:  C Ferri; A L Zignego; S A Pileri
Journal:  J Clin Pathol       Date:  2002-01       Impact factor: 3.411

Review 4.  Hepatitis C virus-associated extrahepatic manifestations: a review.

Authors:  Damien Sène; Nicolas Limal; Patrice Cacoub
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

5.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

6.  Effect of alpha-interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients.

Authors:  C Ferri; A L Zignego; G Longombardo; M Monti; L La Civita; F Lombardini; F Greco; A Mazzoni; G Pasero; P Gentilini
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

7.  Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia.

Authors:  A Gabrielli; A Manzin; M Candela; M L Caniglia; S Paolucci; M G Danieli; M Clementi
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  No evidence for abnormal immune activation in peripheral blood T cells in patients with hepatitis C virus (HCV) infection with or without cryoglobulinaemia. Multivirc Group.

Authors:  P Cacoub; L Musset; P Hausfater; P Ghillani; F L Fabiani; F Charlotte; E Angevin; P Opolon; T Poynard; J C Piette; B Autran
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 9.  Hepatitis C virus infection induced vasculitis.

Authors:  Patrice Cacoub; David Saadoun
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

10.  Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy.

Authors:  Ann W N Auma; Corinne Kowal; Carey L Shive; Alyssa Lange; Sofi Damjanovska; Elizabeth Zebrowski; Elane Reyes; Leonard Calabrese; Lenche Kostadinova; Yngve Falck-Ytter; Maya Mattar; Donald D Anthony
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.